Dermatology Times

@DermTimesNow

A leading news resource serving dermatology clinicians.

North Olmsted, Ohio dermatologytimes.com Joined July 2009

728 Following 32K Followers 24K Posts

Latest posts 5

The latest episode of #DontBeRash is now live!

In this episode, host Dr. Krakowski sits down with leading expert Dr. Joseph Lam for a deep dive into how CALM count, size, age, and associated findings separate benign spots from NF1 and its mimics.

hubs.li/Q04Fc1Kb0

1:20

Dermatology Times @DermTimesNow 19h

Can castor oil grow hair? Does face taping prevent wrinkles?
Swipe through October's Social Media Mythbusters and top stories ↓
hubs.li/Q04F2ywk0

Dermatology Times @DermTimesNow 20h

💡 EXPERT INSIGHTS: For patients living with hidradenitis suppurativa (HS), support can extend beyond traditional medical treatment.

Read more: hubs.li/Q04F8-Gk0

#HidradenitisSuppurativa #PetTherapy #MentalHealth #Dermatology

www.dermatologytimes.com Pet Therapy May Offer Support Beyond the Skin in Hidradenitis Suppurativa | Dermatology Times A case highlights how pet ownership may support mental health, activity, routine, and quality of life in a patient living with hidradenitis suppurativa.

Dermatology Times @DermTimesNow 20h

⭐️ CASE-BASED INSIGHTS: Selecting a hedgehog inhibitor for advanced basal cell carcinoma (BCC) requires more than evaluating efficacy alone.

Read more: hubs.li/Q04F8XcD0

#BasalCellCarcinoma #BCC #SkinCancer #Dermatology

www.dermatologytimes.com Experts Discuss Hedgehog Inhibitor Selection in Advanced BCC | Dermatology Times At a Dermatology Times Case-Based Roundtable, Vishal A. Patel, MD, led a discussion on treatment selection, tolerability, and individualized care for patients with advanced basal cell carcinoma.

Dermatology Times @DermTimesNow 20h

📈 NEW DATA: Phase 3 findings support risankizumab (Skyrizi) as a potential treatment option for pediatric patients with moderate to severe plaque psoriasis.

Read more: hubs.li/Q04F8YgX0

#Risankizumab #PediatricPsoriasis #Psoriasis #Dermatology

www.dermatologytimes.com Phase 3 Trial Supports Risankizumab for Pediatric Psoriasis | Dermatology Times Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.